Bitar Zouheir Ibrahim, Maadarani Ossama Sajeh, Alabdali Fawaz, Teama Ahmed, Elsawah Walid, Mohsen Mohammed Jaber, Elzoueiry Mahmoud Mostafa
Critical Care Unit Ahmadi Hospital Kuwait Oil Company Fahaheel Kuwait.
Head of Endocrinology and Diabetic Unit Ahmadi Hospital Kuwait Oil Company Fahaheel Kuwait.
Clin Case Rep. 2022 Feb 10;10(2):e05440. doi: 10.1002/ccr3.5440. eCollection 2022 Feb.
If not detected early, euglycemic diabetic ketoacidosis can be a serious adverse effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors. Unfortunately, euglycemic diabetic ketoacidosis is underreported in recent trials and missed because of normal blood sugar levels and nonspecific symptoms on presentation. We present two patients with type 2 diabetes mellitus who developed dapagliflozin-associated euglycemic diabetic ketoacidosis followed by hyperglycemic ketoacidosis. The second patient had euglycemic ketoacidosis twice despite instructions to stop using the medication dapagliflozin.
如果未早期发现，正常血糖性糖尿病酮症酸中毒可能是钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的一种严重不良反应。遗憾的是，正常血糖性糖尿病酮症酸中毒在近期试验中报告不足，且由于就诊时血糖水平正常和症状不具特异性而被漏诊。我们报告了两名2型糖尿病患者，他们发生了与达格列净相关的正常血糖性糖尿病酮症酸中毒，随后发展为高血糖性酮症酸中毒。第二名患者尽管已被告知停用达格列净，但仍两次发生正常血糖性酮症酸中毒。
